Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
| Autor: | Mels Hoogendoorn, Eva van den Berg, Eric N. van Roon, Robby E. Kibbelaar, Nic J. G. M. Veeger, Johanne Rozema |
|---|---|
| Přispěvatelé: | PharmacoTherapy, -Epidemiology and -Economics, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Population Comorbidity Malignancy Neoplasms Internal medicine medicine Humans education Aged Proportional Hazards Models education.field_of_study Proportional hazards model business.industry Myelodysplastic syndromes Hazard ratio Neoplasms Second Primary Health Services and Outcomes Hematology medicine.disease Confidence interval Myelodysplastic Syndromes Female Skin cancer business |
| Zdroj: | Blood Adv Blood, 5(5), 1344-1351. AMER SOC HEMATOLOGY |
| ISSN: | 2473-9537 2473-9529 0006-4971 |
| DOI: | 10.1182/bloodadvances.2020003381 |
| Popis: | Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically malignancies. An observational population-based study using the HemoBase registry was performed, including all patients with MDS diagnosed between 2005 and 2017 in Friesland, a Dutch province. Detailed information about diagnosis, patient characteristics, previous treatment of malignancies, and comorbidities according to the Charlson Comorbidity Index (CCI) was collected from electronic health records. Patients were followed up until June 2019. Kaplan-Meier plots and Cox regression analyses were used to study survival differences. In the 291 patients diagnosed with MDS, the median OS was 25.3 months (95% confidence interval [CI], 20.3-30.2). OS was significantly better for patients with CCI score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|